A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Luci indicated the company is focused on securing additional funding opportunities to support the Phase 3 ibezapolstat clinical trial program and expects further updates on funding initiatives in ...

Phase shifters and transmission line technologies are integral components in modern RF and microwave engineering, enabling precise control of signal phase for applications ranging from beamforming in ...

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug. "We are excited to report the top-line results from this important Phase 2 study. VK2735 ...